GlassScriptPhysician profile
Caroline A Mathis
NPI 1467766949
$3,005.09
in general payments reported to CMS, 2019-2025
26 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $1,016 · 2023: $1,092 · 2024: $175 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $458.04 | 2021-2023 | |
| Medtronic, INC. | $329.59 | 2024-2025 | Interstim, Altaviva |
| Daiichi Sankyo INC. | $323.49 | 2021-2023 | Injectafer |
| Novo Nordisk INC | $292.63 | 2021-2023 | Wegovy, Saxenda |
| Pfizer INC. | $164.14 | 2021-2023 | |
| Avion Pharmaceuticals | $160.69 | 2021-2022 | |
| Exeltis, USA INC. | $154.25 | 2022-2023 | Slynd |
| Therapeuticsmd, INC. | $130.15 | 2021-2022 | |
| Amgen INC. | $111.76 | 2022 | |
| Axonics, INC. | $105.53 | 2021 | |
| Sumitomo Pharma America, INC. | $105.11 | 2023 | Myfembree |
| Idorsia Pharmaceuticals US INC | $96.26 | 2023 | Quviviq |
| Evofem Biosciences, INC. | $85.35 | 2021-2023 | Phexxi |
| Organon LLC | $72.88 | 2021-2023 | Nexplanon |
| Agile Therapeutics, INC. | $52.88 | 2022-2023 | Twirla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $52.31 | 2025 | Nxt |
| Mayne Pharma Commercial LLC | $44.80 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.51 | 2021-2023 | |
| Myovant Sciences INC. | $40.34 | 2022 | |
| Coopersurgical, INC. | $38.60 | 2023 | Paragard T 380a |
| Exact Sciences Corporation | $35.59 | 2023 | Cologuard Collection Kit |
| Lupin INC. | $32.18 | 2021 | |
| Boston Scientific Corporation | $27.45 | 2025 | Advantage System |
| Ascend Therapeutics US, LLC | $19.42 | 2023 | |
| Dexcom, INC. | $15.20 | 2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Mathis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.